alpha-[[9-Methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrile

CCG-63802 may be used to study G-protein-mediated cell signaling.

CCG-63802 is a selective, reversible inhibitor of the G protein signaling regulator RGS4. It specifically binds to RGS4 and blocks RGS4-Gαo interaction with IC50 value of 1.9 μM.

CCG-63802 (0.05 mg/kg; intratracheal administration; once per week; 90 days) reduces RGS4 protein expression, leading to partially abrogate the attenuating effect of PGZ on airway inflammation, hyperresponsiveness (AHR), and remodeling .